Latest news with #Ardelyx
Associated Press
21-05-2025
- Business
- Associated Press
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
WALTHAM, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference 2025 on Wednesday, June 4, 2025 at 8:10 am ET in New York. To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at A replay of the fireside chat will be available on the Ardelyx website for 30 days following the event. About Ardelyx Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit and connect with us on X (formerly known as Twitter), LinkedIn and Facebook. Investor and Media Contacts: Caitlin Lowie [email protected]
Yahoo
15-05-2025
- Business
- Yahoo
Exploring 3 US High Growth Tech Stocks For Potential Portfolio Enhancement
As the U.S. stock market experiences mixed movements, with the S&P 500 and Nasdaq on winning streaks amid easing global trade tensions and stable economic data, investors are closely monitoring high-growth tech stocks for potential opportunities. In this dynamic environment, identifying promising tech companies that can enhance a portfolio involves considering factors such as innovation potential, scalability, and resilience to broader market fluctuations. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 26.28% 37.43% ★★★★★★ Ardelyx 20.57% 59.97% ★★★★★★ Legend Biotech 26.73% 59.51% ★★★★★★ Travere Therapeutics 25.39% 64.80% ★★★★★★ TG Therapeutics 25.99% 38.42% ★★★★★★ Alnylam Pharmaceuticals 23.67% 61.11% ★★★★★★ AVITA Medical 27.28% 60.66% ★★★★★★ Alkami Technology 20.54% 76.67% ★★★★★★ Ascendis Pharma 35.16% 60.26% ★★★★★★ Lumentum Holdings 21.59% 110.32% ★★★★★★ Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Autodesk, Inc. offers 3D design, engineering, and entertainment technology solutions globally with a market cap of approximately $63.54 billion. Operations: The company generates revenue primarily from its CAD/CAM software segment, which accounts for $6.13 billion. Autodesk, despite not outpacing the software industry's earnings growth of 23.8% with its own 22.7%, shows robust financial health with a significant Return on Equity forecasted at 44.6% in three years. The company's strategic maneuvers, including the recent $1.5 billion unsecured revolving loan facility, underscore its readiness for future investments and operational flexibility. Innovations like integrating safety and change management tools into Autodesk Construction Cloud® highlight its commitment to enhancing construction project efficiency and transparency, positioning it well within the high-growth tech sector despite slower anticipated revenue growth compared to market leaders. Dive into the specifics of Autodesk here with our thorough health report. Review our historical performance report to gain insights into Autodesk's's past performance. Simply Wall St Growth Rating: ★★★★★☆ Overview: CrowdStrike Holdings, Inc. offers cybersecurity solutions both in the United States and internationally, with a market capitalization of approximately $109.64 billion. Operations: With a market cap of approximately $109.64 billion, CrowdStrike generates revenue primarily through its Security Software & Services segment, which amounts to $3.95 billion. CrowdStrike Holdings continues to redefine cybersecurity with its AI-driven Falcon platform, particularly highlighted by its recent expansion of threat detection capabilities. In April 2025, the company unveiled significant enhancements to Falcon® Identity Protection and Next-Gen SIEM, addressing the sophisticated landscape of cloud threats and identity theft. These innovations not only strengthen security across hybrid environments but also streamline operations by eliminating the need for multiple security tools. This strategic focus on integrated solutions is crucial as CrowdStrike reported a notable revenue increase to $1.06 billion in Q4 FY2025, up from $845 million in the prior year, despite a shift to a net loss in the same period. Unlock comprehensive insights into our analysis of CrowdStrike Holdings stock in this health report. Understand CrowdStrike Holdings' track record by examining our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Datadog, Inc. provides an observability and security platform for cloud applications globally, with a market capitalization of $40.51 billion. Operations: The company generates revenue primarily from its IT Infrastructure segment, which amounts to $2.83 billion. The platform serves both domestic and international markets, focusing on observability and security for cloud applications. Datadog's strategic maneuvering in the tech landscape is underscored by its robust earnings growth of 43.8% over the past year, outpacing the software industry's average of 23.8%. Despite a dip in net income from $42.63 million to $24.64 million in Q1 2025, Datadog forecasts revenue growth between $787 million and $791 million for Q2 and anticipates reaching up to $3.235 billion annually. The partnership with Chainguard enhances its container observability solutions, promising more secure software delivery through proactive CVE remediation—a critical edge as it addresses pressing security vulnerabilities within tech infrastructures. This integration not only broadens Datadog's service offerings but also solidifies its position in a competitive market by aligning enhanced security features with substantial revenue trajectories. Click here and access our complete health analysis report to understand the dynamics of Datadog. Learn about Datadog's historical performance. Discover the full array of 234 US High Growth Tech and AI Stocks right here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:ADSK NasdaqGS:CRWD and NasdaqGS:DDOG. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
12-05-2025
- Automotive
- Yahoo
Exploring 3 High Growth Tech Stocks In The US Market
The recent surge in the U.S. stock market, driven by a temporary easing of trade tensions between the U.S. and China, has seen key indices like the Dow Jones Industrial Average and Nasdaq Composite experience significant gains, particularly benefiting tech stocks. In this buoyant environment, identifying high-growth tech stocks involves looking at companies that are well-positioned to capitalize on technological advancements and market opportunities while demonstrating resilience amid economic fluctuations. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 27.47% 39.60% ★★★★★★ Ardelyx 20.57% 59.97% ★★★★★★ AVITA Medical 27.69% 85.07% ★★★★★★ Clene 65.19% 67.34% ★★★★★★ Travere Therapeutics 28.83% 64.80% ★★★★★★ TG Therapeutics 25.99% 38.42% ★★★★★★ Alnylam Pharmaceuticals 23.67% 61.11% ★★★★★★ Lumentum Holdings 21.54% 110.32% ★★★★★★ Alkami Technology 22.46% 76.67% ★★★★★★ Ascendis Pharma 35.16% 60.26% ★★★★★★ Click here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener. We'll examine a selection from our screener results. Simply Wall St Growth Rating: ★★★★☆☆ Overview: CarGurus, Inc. operates an online automotive platform for buying and selling vehicles in the United States and internationally, with a market capitalization of approximately $3.07 billion. Operations: The company generates revenue primarily from its U.S. Marketplace segment, which accounts for $755.93 million, and its Digital Wholesale segment, contributing $82.13 million. CarGurus, Inc. has demonstrated robust financial performance with a notable rebound in its quarterly earnings, as Q1 2025 saw net income soaring to $39.05 million from $21.3 million the previous year, alongside an increase in sales from $187.22 million to $212.24 million. This growth trajectory is underpinned by strategic executive shifts, with CEO Jason Trevisan taking on additional financial oversight roles, potentially steering the company through innovative fiscal strategies and operational efficiencies. Despite facing challenges like a one-off loss of $144.4M affecting past earnings quality and revenue growth forecasts trailing behind the U.S market at 6.9% annually versus 8.4%, CarGurus is poised for significant earnings expansion at an expected annual rate of 32.5%. These dynamics suggest a resilient adaptability and potential for sustained profitability within the competitive tech landscape. Unlock comprehensive insights into our analysis of CarGurus stock in this health report. Gain insights into CarGurus' historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Hut 8 Corp. is a vertically integrated operator of energy infrastructure and Bitcoin mining in North America, with a market cap of $1.45 billion. Operations: The company generates revenue primarily through its power and digital infrastructure segments, with $46.83 million from power and $20.99 million from digital infrastructure. Despite a challenging Q1 2025, where Hut 8 reported a net loss of $133.89 million and a significant drop in revenue to $21.82 million from the previous year's $51.74 million, the company is positioning itself strategically within the tech sector through its new venture, American Bitcoin. This initiative focuses on industrial-scale Bitcoin mining and marks a pivotal shift in Hut 8's business model following its majority stake acquisition in American Data Centers Inc., now rebranded as American Bitcoin. The move underlines Hut 8's commitment to innovating within the cryptocurrency mining industry despite recent financial volatilities, aiming to leverage technological advancements for future growth. Delve into the full analysis health report here for a deeper understanding of Hut 8. Evaluate Hut 8's historical performance by accessing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: TaskUs, Inc. offers outsourced digital services to companies across the Philippines, the United States, India, and other international markets with a market capitalization of approximately $1.52 billion. Operations: TaskUs specializes in providing outsourced digital services, focusing on customer support and content moderation for global clients. The company generates revenue primarily from service fees charged to its clients across various geographical markets. TaskUs has demonstrated a robust performance in Q1 2025 with net income rising to $21.15 million from $11.71 million the previous year, reflecting a notable increase in profitability and operational efficiency. This growth is underpinned by strategic expansions such as the recent launch of its Agentic AI Consulting practice, which positions the company at the forefront of AI-driven business process optimization. Moreover, TaskUs's deepening engagement with high-profile clients through advanced AI solutions underscores its commitment to integrating cutting-edge technology across various industries. The company's ability to nearly double its earnings per share from continuing operations year-over-year, combined with a significant buyout offer from an affiliate of Blackstone at $16.50 per share, signals strong confidence in its future trajectory and strategic direction within the tech sector. Take a closer look at TaskUs' potential here in our health report. Review our historical performance report to gain insights into TaskUs''s past performance. Get an in-depth perspective on all 237 US High Growth Tech and AI Stocks by using our screener here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:CARG NasdaqGS:HUT and NasdaqGS:TASK. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
01-05-2025
- Business
- Yahoo
High Growth Tech Stocks In The US For May 2025
As the U.S. market experiences a notable upswing, with the S&P 500 and Nasdaq Composite marking gains amid strong earnings reports from major tech companies like Microsoft and Meta, investors are keenly observing how these developments impact high-growth tech stocks. In this environment of robust AI spending and positive sentiment, identifying companies with solid financials and innovative strategies becomes crucial for those looking to tap into the potential of high-growth sectors. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 20.35% 33.99% ★★★★★★ Travere Therapeutics 28.65% 66.06% ★★★★★★ TG Therapeutics 26.06% 37.39% ★★★★★★ Arcutis Biotherapeutics 26.11% 58.46% ★★★★★★ Clene 62.08% 64.01% ★★★★★★ Alnylam Pharmaceuticals 23.08% 58.85% ★★★★★★ AVITA Medical 27.81% 55.17% ★★★★★★ Alkami Technology 20.71% 92.32% ★★★★★★ Ascendis Pharma 32.75% 59.64% ★★★★★★ Lumentum Holdings 21.34% 120.49% ★★★★★★ Click here to see the full list of 236 stocks from our US High Growth Tech and AI Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Growth Rating: ★★★★★☆ Overview: Ardelyx, Inc. focuses on discovering, developing, and commercializing medicines for unmet medical needs globally, with a market cap of $1.30 billion. Operations: Ardelyx generates revenue primarily through the development and commercialization of biopharmaceutical products, totaling $333.62 million. Ardelyx's recent appointment of Dr. Merdad Parsey to its Board underscores a strategic enhancement in governance, potentially enriching its leadership amidst crucial clinical advancements. The company's innovative focus is exemplified by XPHOZAH®, a pioneering treatment for hyperphosphatemia in CKD patients on dialysis, reflecting Ardelyx's commitment to addressing unmet medical needs through novel therapeutic approaches. Financially, Ardelyx has shown significant traction with a revenue jump to $333.62 million from the previous year's $124.46 million, alongside an anticipated transition to profitability within three years, suggesting robust growth prospects driven by both clinical outcomes and market expansion strategies. Unlock comprehensive insights into our analysis of Ardelyx stock in this health report. Review our historical performance report to gain insights into Ardelyx's's past performance. Simply Wall St Growth Rating: ★★★★★☆ Overview: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutic compounds for diseases with significant unmet needs, with a market cap of approximately $2.41 billion. Operations: Apellis Pharmaceuticals focuses on developing and commercializing proprietary therapeutics, generating revenue of $781.37 million. Apellis Pharmaceuticals, set to become profitable within three years, is navigating a transformative phase with strategic board enhancements and significant FDA approvals. Recently, Craig Wheeler joined the board, bringing extensive biopharmaceutical leadership. This governance boost coincides with the FDA's priority review of EMPAVELI for severe kidney diseases—a potential market expander given its $212.53 million Q4 revenue up from $146.38 million last year. With earnings expected to grow 61.29% annually and R&D focused on critical care areas, Apellis is poised for impactful industry contributions amidst forecasts of high return on equity (690.6%) in the near future. Click to explore a detailed breakdown of our findings in Apellis Pharmaceuticals' health report. Gain insights into Apellis Pharmaceuticals' past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: RingCentral, Inc. offers cloud-based business communications and contact center solutions globally, with a market capitalization of approximately $2.29 billion. Operations: RingCentral generates revenue primarily from its Internet Software & Services segment, totaling approximately $2.40 billion. The company focuses on providing cloud-based communication and contact center solutions across North America and internationally. RingCentral's strategic maneuvers in 2025, including the extension of its credit facilities and key partnerships with PCI-PAL and Cox Business, underscore its commitment to expanding its innovative cloud communication solutions. Notably, the company's recent integration with PCI-PAL enhances secure payment capabilities across North America and Europe, a critical feature for maintaining compliance and customer trust in digital transactions. Furthermore, the collaboration with Cox Business is set to transform work experiences by leveraging RingCentral's AI-driven communication platform. These initiatives are pivotal as RingCentral navigates through a competitive landscape marked by a need for high security and seamless customer interactions in cloud communications. Click here and access our complete health analysis report to understand the dynamics of RingCentral. Evaluate RingCentral's historical performance by accessing our past performance report. Unlock our comprehensive list of 236 US High Growth Tech and AI Stocks by clicking here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:ARDX NasdaqGS:APLS and NYSE:RNG. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
01-05-2025
- Business
- Yahoo
High Growth Tech Stocks In The US For May 2025
As the U.S. market experiences a notable upswing, with the S&P 500 and Nasdaq Composite marking gains amid strong earnings reports from major tech companies like Microsoft and Meta, investors are keenly observing how these developments impact high-growth tech stocks. In this environment of robust AI spending and positive sentiment, identifying companies with solid financials and innovative strategies becomes crucial for those looking to tap into the potential of high-growth sectors. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 20.35% 33.99% ★★★★★★ Travere Therapeutics 28.65% 66.06% ★★★★★★ TG Therapeutics 26.06% 37.39% ★★★★★★ Arcutis Biotherapeutics 26.11% 58.46% ★★★★★★ Clene 62.08% 64.01% ★★★★★★ Alnylam Pharmaceuticals 23.08% 58.85% ★★★★★★ AVITA Medical 27.81% 55.17% ★★★★★★ Alkami Technology 20.71% 92.32% ★★★★★★ Ascendis Pharma 32.75% 59.64% ★★★★★★ Lumentum Holdings 21.34% 120.49% ★★★★★★ Click here to see the full list of 236 stocks from our US High Growth Tech and AI Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Growth Rating: ★★★★★☆ Overview: Ardelyx, Inc. focuses on discovering, developing, and commercializing medicines for unmet medical needs globally, with a market cap of $1.30 billion. Operations: Ardelyx generates revenue primarily through the development and commercialization of biopharmaceutical products, totaling $333.62 million. Ardelyx's recent appointment of Dr. Merdad Parsey to its Board underscores a strategic enhancement in governance, potentially enriching its leadership amidst crucial clinical advancements. The company's innovative focus is exemplified by XPHOZAH®, a pioneering treatment for hyperphosphatemia in CKD patients on dialysis, reflecting Ardelyx's commitment to addressing unmet medical needs through novel therapeutic approaches. Financially, Ardelyx has shown significant traction with a revenue jump to $333.62 million from the previous year's $124.46 million, alongside an anticipated transition to profitability within three years, suggesting robust growth prospects driven by both clinical outcomes and market expansion strategies. Unlock comprehensive insights into our analysis of Ardelyx stock in this health report. Review our historical performance report to gain insights into Ardelyx's's past performance. Simply Wall St Growth Rating: ★★★★★☆ Overview: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutic compounds for diseases with significant unmet needs, with a market cap of approximately $2.41 billion. Operations: Apellis Pharmaceuticals focuses on developing and commercializing proprietary therapeutics, generating revenue of $781.37 million. Apellis Pharmaceuticals, set to become profitable within three years, is navigating a transformative phase with strategic board enhancements and significant FDA approvals. Recently, Craig Wheeler joined the board, bringing extensive biopharmaceutical leadership. This governance boost coincides with the FDA's priority review of EMPAVELI for severe kidney diseases—a potential market expander given its $212.53 million Q4 revenue up from $146.38 million last year. With earnings expected to grow 61.29% annually and R&D focused on critical care areas, Apellis is poised for impactful industry contributions amidst forecasts of high return on equity (690.6%) in the near future. Click to explore a detailed breakdown of our findings in Apellis Pharmaceuticals' health report. Gain insights into Apellis Pharmaceuticals' past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: RingCentral, Inc. offers cloud-based business communications and contact center solutions globally, with a market capitalization of approximately $2.29 billion. Operations: RingCentral generates revenue primarily from its Internet Software & Services segment, totaling approximately $2.40 billion. The company focuses on providing cloud-based communication and contact center solutions across North America and internationally. RingCentral's strategic maneuvers in 2025, including the extension of its credit facilities and key partnerships with PCI-PAL and Cox Business, underscore its commitment to expanding its innovative cloud communication solutions. Notably, the company's recent integration with PCI-PAL enhances secure payment capabilities across North America and Europe, a critical feature for maintaining compliance and customer trust in digital transactions. Furthermore, the collaboration with Cox Business is set to transform work experiences by leveraging RingCentral's AI-driven communication platform. These initiatives are pivotal as RingCentral navigates through a competitive landscape marked by a need for high security and seamless customer interactions in cloud communications. Click here and access our complete health analysis report to understand the dynamics of RingCentral. Evaluate RingCentral's historical performance by accessing our past performance report. Unlock our comprehensive list of 236 US High Growth Tech and AI Stocks by clicking here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:ARDX NasdaqGS:APLS and NYSE:RNG. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
